Latest News

Pearlman and Griggs tackle the real-world challenges of innovation—from surgeon comfort zones and patient perceptions to equipment logistics in private practice.

"I'm very excited to bring this therapy to our patients in the Philadelphia area and to be able to offer it at MidLantic," says David Cahn, DO, MBS, FACOS.

"For me and the patients, [nadofaragene firadenovec is] a very convenient dosing schedule, and it's a very efficacious treatment," says Ravi D. Chauhan, MD, FACS.

Miner emphasized that TRAVERSE has reshaped the safety narrative around testosterone replacement therapy, easing concerns about cardiovascular and prostate risks.

"I think the most important thing, or take-home message that we try to share, is gathering data, understanding what those metrics are from the very beginning," says Brooke B. Edwards, MD.

"The more I use [SURE], the more applications I see with it," says Matthew A. Love, MD.

"The main issue in DC now is the Medicare Physician Fee Schedule," says Scott Sellinger, MD, FACS.

The FDA has confirmed that results from the UTOPIA trial can support submission of an NDA for UGN-103.

The study is assessing FL115 in combination with BCG in patients with non-muscle invasive bladder cancer.

The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.

The approval is supported by the phase 2/3 ZEUS trial.

A key highlight of the discussion is the emerging research on testosterone in women, an area long underfunded and under-studied.

The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.